Tenax Therapeutics Company Insiders
| TENX Stock | USD 5.36 0.03 0.56% |
Slightly above 93 percent of all Tenax Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Tenax Therapeutics suggests that a fairly large number of insiders are very bullish. Tenax Therapeutics employs about 5 people. The company is managed by 7 executives with a total tenure of roughly 22 years, averaging almost 3.0 years of service per executive, having 0.71 employees per reported executive.
| Douglas Hay President Executive Vice President - Regulatory Affairs |
Tenax Therapeutics' Insider Buying Vs Selling
93
Selling | Buying |
Latest Trades
| 2020-09-08 | Armistice Capital, Llc | Acquired 8543 @ 1.46 | View | ||
| 2020-09-04 | Armistice Capital, Llc | Acquired 23457 @ 1.41 | View | ||
| 2020-09-02 | Armistice Capital, Llc | Acquired 20000 @ 1.47 | View | ||
| 2020-08-31 | Armistice Capital, Llc | Acquired 20000 @ 1.45 | View | ||
| 2020-08-27 | Armistice Capital, Llc | Acquired 12000 @ 1.5 | View | ||
| 2020-08-26 | Armistice Capital Master Fund | Acquired 34903 @ 1.51 | View | ||
| 2020-08-24 | Armistice Capital, Llc | Acquired 5692 @ 1.47 | View | ||
| 2020-08-21 | Armistice Capital, Llc | Acquired 116242 @ 1.44 | View | ||
| 2020-08-19 | Armistice Capital, Llc | Acquired 70767 @ 1.45 | View | ||
| 2020-05-18 | Ronald R Blanck | Acquired 5000 @ 1.09 | View | ||
| 2017-12-18 | Ronald R Blanck | Acquired 12950 @ 0.45 | View | ||
| 2017-11-14 | Ronald R Blanck | Disposed 12950 @ 0.39 | View | ||
| 2016-11-23 | Gerald T Proehl | Acquired 29882 @ 1.67 | View | ||
| 2015-11-19 | Ronald R Blanck | Acquired 4700 @ 3.26 | View | ||
| 2015-01-20 | Ronald R Blanck | Acquired 2000 @ 3.49 | View |
Monitoring Tenax Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Tenax |
Tenax Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tenax Therapeutics' future performance. Based on our forecasts, it is anticipated that Tenax will maintain a workforce of slightly above 10 employees by January 2025.Tenax Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6609) % which means that it has lost $0.6609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1379) %, meaning that it created substantial loss on money invested by shareholders. Tenax Therapeutics' management efficiency ratios could be used to measure how well Tenax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to rise to -0.97 in 2024. At this time, Tenax Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2 M in 2024, whereas Non Current Assets Total are likely to drop 1,061 in 2024.Common Stock Shares Outstanding is likely to rise to about 260.9 K in 2024, despite the fact that Net Loss is likely to grow to (27.8 M).
Tenax Therapeutics Workforce Comparison
Tenax Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 198. Tenax Therapeutics holds roughly 5.0 in number of employees claiming about 2.53% of equities under Health Care industry.
Tenax Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenax Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenax Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tenax Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2022-09-01 | 0.5 | 1 | 2 | 1,909,585 | 2,477,456 |
| 2022-06-01 | 13.0 | 13 | 1 | 11,043,527 | 2,072,538 |
| 2021-12-01 | 0.6667 | 2 | 3 | 3,819,170 | 3,819,170 |
| 2021-09-01 | 3.0 | 3 | 1 | 9,596,538 | 250,000 |
| 2021-06-01 | 2.0 | 8 | 4 | 7,191,750 | 575,034 |
| 2021-03-01 | 1.0 | 5 | 5 | 1,076,098 | 0.00 |
| 2020-09-01 | 6.5 | 26 | 4 | 496,384 | 13,043,621 |
| 2020-03-01 | 2.0 | 2 | 1 | 150,000 | 2,360,313 |
| 2017-12-01 | 3.0 | 3 | 1 | 13,048 | 12,950 |
| 2017-03-01 | 1.0 | 1 | 1 | 213,420 | 96,999 |
| 2016-09-01 | 1.0 | 1 | 1 | 10,000 | 49.00 |
| 2016-06-01 | 2.0 | 2 | 1 | 3,930 | 55.00 |
| 2011-12-01 | 0.75 | 3 | 4 | 10,096 | 10,331 |
| 2011-06-01 | 4.5 | 9 | 2 | 299,725 | 806.00 |
| 2011-03-01 | 2.4 | 12 | 5 | 11,343 | 2,015 |
| 2010-12-01 | 3.75 | 15 | 4 | 24,963 | 1,812 |
| 2010-09-01 | 9.0 | 9 | 1 | 14,664 | 667.00 |
| 2010-06-01 | 7.0 | 7 | 1 | 6,573 | 2,000 |
| 2010-03-01 | 0.6667 | 4 | 6 | 4,002 | 10,667 |
Tenax Therapeutics Notable Stakeholders
A Tenax Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tenax Therapeutics often face trade-offs trying to please all of them. Tenax Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tenax Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Christopher Giordano | President CEO | Profile | |
| Douglas Hay | Executive Vice President - Regulatory Affairs | Profile | |
| Doug Randall | Executive VP of Commercial and Bus. Operations | Profile | |
| Stuart MD | Chief Director | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Nancy Hecox | Gen Affairs | Profile | |
| Esq CPA | Interim Officer | Profile |
About Tenax Therapeutics Management Performance
The success or failure of an entity such as Tenax Therapeutics often depends on how effective the management is. Tenax Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tenax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tenax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (1.02) | (0.97) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.95) | (0.90) |
Please note, the imprecision that can be found in Tenax Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tenax Therapeutics. Check Tenax Therapeutics' Beneish M Score to see the likelihood of Tenax Therapeutics' management manipulating its earnings.
Tenax Therapeutics Workforce Analysis
Traditionally, organizations such as Tenax Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tenax Therapeutics within its industry.Tenax Therapeutics Manpower Efficiency
Return on Tenax Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 1.2M |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.